Shares Jump as Foamix Pharma's FDX104 Shows Efficacy in Phase II Study
Foamix Announces Positive Top-Line Results From Phase II Study for FDX104 (Doxycycline Foam) in the Prevention of Acneiform Rash Associated With Targeted Antibody Treatments for Colon and Head and Neck Cancers
- Company to Advance Clinical Program for Lead Complement Inhibitor, TNT009, in Cold Agglutinin Disease and Other Rare Diseases
- Company to Advance Clinical Program for Lead Complement Inhibitor, TNT009, in Cold Agglutinin Disease and Other Rare Diseases